Quadrant Capital Group’s CorMedix CRMD Stock Holding History

Quadrant Capital Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-625	Closed	-$4.24K	–	1534
2026 Q1	$4.24K	Buy	+625	New	+$4.62K	﹤0.01%	2391

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Quadrant Capital Group's CRMD Position: Q2 2026 in Review

Quadrant Capital Group sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 625 shares — an estimated $4.24K sold.

Quadrant Capital Group first reported a position in CRMD in Q1 2026 and held it in 1 quarter. The position peaked at $4.24K in Q1 2026. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Quadrant Capital Group reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 625 CorMedix shares in Q2 2026, an estimated $4.24K.
Quadrant Capital Group first reported a position in CorMedix in Q1 2026 and held it in 1 quarter.
Quadrant Capital Group's CorMedix position peaked at $4.24K in Q1 2026.
193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.